Jefferies lowered the firm’s price target on ResMed to $158 from $165 and keeps a Hold rating on the shares after the company reported fiscal Q1 results. Overall device growth and margins “disappointed,” said the firm, which is lowering its estimates, but Jefferies added that ResMed said it is not seeing a GLP1 impact and argued a large market will remain.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RMD: